De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial
GLP-1 Drugs, Additional Positive Effects 01:30:14 GLP-1-Plus Development, Tirzepatide, Mounjaro, AMG 133 01:34:49 Alpha-MSH & Pharmacology 01:40:41 Dopamine, Eating & Context 01:46:01 Dopamine & Learning, Water Content & Food 01:53:23 Salt, Water & Thirst 02:03:27 Hunger vs
Mavraganis 1 , C
Tip: We are programming your system to burn calories immediately and not store them
Discussion Here we report the development of a unimolecular quintuple agonist that combines the body weight and blood glucose-lowering effects of GLP-1GIP co-agonism with the insulin-sensitizing and anti-inflammatory properties of the nuclear-acting PPAR// triple agonist Lani through targeted delivery into cells expressing GLP-1R and/or GIPR